rs10958409 — SOX17

Intergenic variant near SOX17 at 8q11 that reduces expression of this endothelial transcription factor, increasing susceptibility to intracranial aneurysm and cerebrovascular instability.

See your personal result for SOX17

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SOX17 and the Fragile Vessel Wall — A Genetic Risk Factor for Brain Aneurysm

Every blood vessel in the brain depends on a thin inner lining of endothelial cells to remain structurally sound. SOX1711 SOX17
SRY-box transcription factor 17, a master regulator of endothelial cell identity and arterial specification is one of the key proteins that keeps that lining intact. The variant rs10958409, located in a regulatory region near SOX17 on chromosome 8q11, subtly reduces SOX17 activity — and in doing so, increases the risk that cerebral artery walls will weaken and balloon out into an intracranial aneurysm22 intracranial aneurysm
A bulge or sac in a brain artery that can rupture and cause hemorrhagic stroke; affects roughly 1–3% of the population.

The Mechanism

SOX17 is an HMG-box transcription factor expressed preferentially in arterial endothelial cells. It drives the arterial identity program — activating genes that keep endothelial cells cohesive, aligned, and resistant to haemodynamic stress — while suppressing venous cell fates. Without adequate SOX17 signaling, arterial endothelial cells lose some of their identity, tight junctions between cells become less stable, and the subendothelial matrix receives weaker maintenance signals. This compromises vessel wall structural integrity, particularly at branch points and bifurcations where blood flow is turbulent — exactly where intracranial aneurysms form.

rs10958409 is an intergenic variant upstream of the SOX17 coding sequence. It lies within a regulatory region and is thought to influence the level of SOX17 transcription rather than change the protein itself. The result is a quantitative reduction in endothelial SOX17 expression in A-allele carriers, making them more susceptible to the vessel wall weakening that precedes aneurysm formation.

The original discovery33 original discovery
Bilguvar et al. identified three susceptibility loci for intracranial aneurysm in a combined European and Japanese cohort; the 8q11 locus was one of the three, with OR ~1.28 in over 10,000 individuals explicitly noted that "associated SNPs on 8q likely act via SOX17, which is required for formation and maintenance of endothelial cells."

The Evidence

The rs10958409 association with intracranial aneurysm is one of the most replicated genetic findings in cerebrovascular disease. The Neurology 2013 meta-analysis44 Neurology 2013 meta-analysis
Alg et al. combined 61 studies with 32,887 IA cases and 83,683 controls — the largest meta-analysis of IA genetics at the time confirmed rs10958409 with OR 1.19 (95% CI 1.13–1.26) — a modest but highly consistent per-allele effect. A second large GWAS by Yasuno et al. in 5,891 IA cases and 14,181 controls55 Yasuno et al. in 5,891 IA cases and 14,181 controls
Nature Genetics 2010; confirmed the SOX17 locus at OR 1.28, P=1.3×10⁻¹² across European and Japanese populations independently.

In a North American family-based replication study of 406 IA cases and 392 controls, Deka et al.66 Deka et al.
Stroke 2010 — focused on familial IA cases, which enriches for genetic effects found rs10958409 to be the strongest replicating variant at OR 1.86 (95% CI 1.40–2.47, allelic P=1.3×10⁻⁵). Critically, they documented a multiplicative interaction between this variant and smoking — the combination of smoking and A-allele carriage compounded aneurysm risk beyond what either factor predicted alone.

A Chinese case-control study Wang et al. Hum Genet 201277 Wang et al. Hum Genet 2012
451 stroke cases and 831 controls found that women carrying the A allele at rs10958409 who also used combined oral contraceptives had a 4.81-fold increased risk of hemorrhagic stroke compared to non-carriers not using OCs — a dramatic gene-drug interaction for a relatively common variant.

In East-Asian populations, Hong et al. World Neurosurg 201888 Hong et al. World Neurosurg 2018
meta-analysis of 5,100 IA cases and 7,930 controls from East Asia confirmed rs10958409 with OR 1.11 (95% CI 1.04–1.19, p=0.0023).

Practical Actions

The cerebrovascular implications of this variant are specific and actionable. Because SOX17 deficiency impairs endothelial integrity, maintaining vascular health at the physiological level — blood pressure control, avoiding vascular endothelium-damaging exposures — is particularly relevant. The gene-smoking and gene-OC interactions documented in the literature give concrete avoidance targets for A-allele carriers.

Intracranial aneurysms are silent until they rupture, making detection the key intervention. Brain MRI/MRA aneurysm screening is available and is cost-effective for individuals with both genetic risk and positive family history.

Interactions

rs10958409 interacts multiplicatively with cigarette smoking — Deka et al. Stroke 2010 specifically documented this interaction in familial IA cases. Smoking causes direct endothelial injury through oxidative stress and inflammation, which may compound the structural vulnerability created by reduced SOX17 expression.

The combined oral contraceptive interaction documented in Wang et al. 2012 is particularly relevant: OC-associated thrombophilia and haemodynamic changes in cerebral arteries appear to compound the endothelial vulnerability from reduced SOX17. Female A-allele carriers should discuss OC risks explicitly with their physician.

rs9298506 (also near SOX17 on 8q11) shows a correlated signal (OR 1.19–1.21 in the same studies) and is likely capturing the same or a closely related regulatory effect. rs1333049 and rs10757278 at the 9p21 locus represent a second, independent intracranial aneurysm risk signal.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal

No elevated SOX17 aneurysm risk from rs10958409

You carry two copies of the G reference allele at rs10958409, the most common genotype at this locus. Approximately 69% of people of European ancestry share your GG genotype. This variant does not contribute elevated intracranial aneurysm risk from this SOX17 regulatory locus. Standard cerebrovascular risk assessment based on your other risk factors — blood pressure, family history, smoking status — applies without modification from this genetic signal.

AG Elevated Aneurysm Risk Intermediate

One A risk allele — moderately increased intracranial aneurysm risk

Your AG genotype places you among approximately 28% of Europeans and up to 50% of South Asians carrying one A allele at this regulatory variant near SOX17. The association between rs10958409 and intracranial aneurysm (IA) was first identified in a joint European and Japanese GWAS (Bilguvar et al. 2008, PMID 18997786) and has been independently replicated across Finnish, Dutch, Japanese, East Asian, and North American cohorts.

The 2013 Neurology meta-analysis (32,887 cases; 83,683 controls) confirmed OR 1.19 per A allele. A second GWAS (Yasuno et al. Nat Genet 2010, 5,891 cases) confirmed OR 1.28. In the North American familial IA study (Deka et al. Stroke 2010), the variant showed OR 1.86 — a larger effect possibly reflecting enrichment for genetic contributors in familial cases.

The smoking interaction is particularly important: Deka et al. documented that carrying this variant combined with cigarette smoking was associated with IA risk in a multiplicative rather than additive pattern. This means smoking is not just independently additive to your genetic risk — it amplifies the genetic signal.

For women, the Wang et al. 2012 Chinese case-control study (451 stroke cases) found that A-allele carriers on combined oral contraceptives had 4.81-fold increased hemorrhagic stroke risk compared to non-carrier non-OC users — a dramatic interaction that makes OC counseling a specific genetic consideration.

AA High Aneurysm Risk High Risk

Two A risk alleles — significantly elevated intracranial aneurysm risk

As an AA homozygote, you carry the maximum genetic load at the rs10958409 SOX17 regulatory locus. This variant was identified in the landmark 2008 Nature Genetics GWAS by Bilguvar et al. (>10,000 individuals across Finland, the Netherlands, and Japan) and confirmed in a second major GWAS (Yasuno et al. 2010, 5,891 cases) with OR 1.28 per allele at P=1.3×10⁻¹². The 2013 Neurology meta-analysis of 116,000+ individuals reported OR 1.19 per allele. For AA homozygotes, multiplying two such per-allele effects gives an expected OR of approximately 1.42–1.64 vs GG carriers.

The key biological mechanism is a quantitative reduction in SOX17 transcription in arterial endothelial cells. SOX17 is required for arterial identity and structural maintenance — reduced expression weakens the tight junctions and extracellular matrix signals that keep cerebral artery walls resistant to haemodynamic stress. This is most dangerous at arterial bifurcations (the circle of Willis branch points) where intracranial aneurysms classically form.

The North American familial IA study (Deka et al. Stroke 2010, PMID 20190001) found OR 1.86 for this variant, with a multiplicative smoking interaction. At AA homozygosity, both alleles contribute this amplified interaction with smoking. The Chinese OC study (Wang et al. 2012) documented 4.81-fold hemorrhagic stroke risk in A-allele carriers on combined OCs — an interaction that applies with greater force at two A alleles.

Intracranial aneurysms are clinically silent until rupture. Given your elevated genetic risk, proactive imaging (MRI/MRA) is warranted, especially in the presence of family history or modifiable risk factors.